



# Lyka Labs Limited

MANUFACTURERS OF PHARMACEUTICALS.

Regd. Office: 4801/B & 4802/A, GIDC Industrial Estate, Ankleshwar-393002.  
Administrative Office: 101, Shiv Shakti Industrial Estate, Andheri-Kurla Rd., Andheri (East), Mumbai -400059.

## UNAUDITED FINANCIAL RESULTS [PROVISIONAL] FOR THE QUARTER ENDED 30TH JUNE, 2009

(Rs. in Lacs)

Sr. No.	Particulars	Quarter Ended 30.06.2009 (Unaudited)	Quarter Ended 30.06.2008 (Unaudited)	15 Months Ended 30.06.2009 (Unaudited)	12 Months Ended 31.03.2008 (Audited)
1.	a) Net Sales/Income from operations	2742.57	2190.43	12216.01	10568.74
	less : Excise duty paid	144.57	221.33	855.33	1590.93
		2598.00	1969.10	11360.68	8977.81
	b) Other Operating Income	29.03	21.72	79.83	352.89
	Total Income (1 a+b)	2627.03	1990.82	11440.51	9330.70
2.	Expenditure				
	a) (Increase)/Decrease in Stock in trade and work in progress	-83.95	-215.51	21.77	-232.09
	b) Consumption of Materials	1447.93	1323.66	6640.84	4683.07
	c) Purchase of traded goods	666.52	75.32	1882.89	1694.86
	d) Employee cost	205.26	199.06	1124.20	776.70
	e) Depreciation	72.86	37.72	240.32	128.69
	f) Other Expenditure	305.60	303.49	1402.78	1532.92
	g) Total expenditure	2614.22	1723.74	11312.80	8584.15
3.	Profit/(Loss) from Operations before Other Income, Interest and Exceptional items (1-2)	12.81	267.08	127.71	746.55
4.	Other Income	205.18	55.38	707.28	419.58
5.	Profit before interest & Exceptional Items (3+4)	217.99	322.46	834.99	1166.13
6.	Interest and Finance Charges - nett - (note 6)	244.11	170.72	1119.95	714.14
7.	Profit/(Loss) after Interest but before exceptional Items (5-6)	-26.12	151.74	-284.96	451.99
8.	Exceptional Items	0.00	0.00	0.00	0.00
9.	Profit/(Loss) from Ordinary Activities before tax (7+8)	-26.12	151.74	-284.96	451.99
10.	Tax Expenses - FBT	1.40	4.00	15.40	33.10
11.	Net Profit/(Loss) from Ordinary activities after tax (9-10)	-27.52	147.74	-300.36	418.89
12.	Extraordinary Item (net of tax expenses)	0.00	0.00	0.00	0.00
13.	Net Profit/(Loss) for the period (11-12)	-27.52	147.74	-300.36	418.89
14.	Paid up equity share capital (face value Rs.10/- per share)	2158.00	2158.00	2158.00	2093.00
15.	Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year				5364.32
16.	Earnings Per Share				
	basic and diluted (not annulised)	-0.13	0.71	-1.39	2.46
17.	Public Shareholding number of shares	16552735	16552735	16552735	16552735
	percentage of shareholding	76.70	76.70	76.70	79.09
18.	Promoters and promoter group - Shareholding				
	a) Pledged / Encumbered				
	- Numbers of Shares	2431715	-	2431715	-
	- Percentage of shares (as a % of the total shareholding or promoter and promoter group)	48.37	-	48.37	-
	- Percentage of shares (as a % of the total share capital of the company)	11.27	-	11.27	-
	b) Non - encumbered				
	- Number of shares	2595550	-	2595550	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	51.63	-	51.63	-
	- Percentage of shares (as a % of the total share capital of the company)	12.03	-	12.03	-

### Notes:

- The above results were duly considered by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on 31st July, 2009.
- Lyka BDR International Ltd., has become a subsidiary of the Company w.e.f. 04/05/2009.
- Depreciation includes Rs. 30.46 lacs on Revaluation of Assets during the quarter and cumulative 15 months period.
- Consequent upon the issue of Notification dated 31st March, 2009 by the Department of Companies Affairs, permitting retrospectively to reverse the loss or gain on exchange earlier provided till 2011 to be amortised thereafter, of Rs. 277.65 lacs in the accounts to the Profit & Loss Account in AS 11 and have transferred the same to 'Foreign currency monetary items Translation Difference Account'. Accordingly there is a change in accounting policy; as a result the loss for the year is under stated.
- The Company's Lyophilised Bulk Drugs & Formulation Plant at Ankleshwar which was closed for upgradation, modernisation and additional capacity has become fully operational from June '09.
- Interest and finance charges are nett of Rs. 69.16 lacs being capitalised interest in respect of uncommissioned plant appearing in work-in-progress.
- Other Income includes insurance claim receivable of Rs. 112.14 lacs due to fire at one of the loan licensee unit.
- Tax provision if any, would be provided at the year end in respect of completed assessments. No provision for Fringe Benefit Tax has been made in view of deletion of such provisions in the Finance Bill 2009.
- R & D expenditure have been deferred as in the past.
- The Company has one Single Segment "Pharmaceuticals".
- No complaint of Investors received during the quarter.
- Previous periods figures have been regrouped/rearranged wherever necessary.
- Audit qualifications in respect of Audited Accounts for 2007-08 and management comments thereon are detailed below:
  - The deferment of R & D expenditure of Rs.2,75,14,204/- which is not in compliance with Accounting Standard (AS-26). The Company has explained at note No. 13 to the accounts.
  - Regarding non-provision of slow/non moving inventories of Rs. 1,21,68,172/- as explained at note No. 14 to the accounts.

For LYKA LABS LIMITED  
(N. I. GANDHI)

Chairman & Managing Director

Place : Mumbai

Dated : 31st July, 2009

PRESSMAN